跳至主要内容
临床试验/EUCTR2011-004217-17-Outside-EU/EEA
EUCTR2011-004217-17-Outside-EU/EEA进行中(未招募)不适用

A single-arm, open-label study of the Palatability and Tolerability of Exjade Taken with Meals, with Different Liquids or Crushed and Added to Food

ovartis Pharmaceuticals Corporation0 个研究点目标入组 65 人开始时间: 2011年12月9日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
65

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Male or female patients with thalassemia major, sickle cell disease (SCD), low or intermediate 1 (INT 1) risk myelodysplastic syndrome (MDS) or other anemias and transfusional hemosiderosis.
  • 2.Patients who were on, starting, or resuming treatment with Exjade.
  • 3.Patients who were >2 years (i.e., 2 years of age or older).
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 20
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 45
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 1

排除标准

  • 1.Serum creatinine above the upper limit of normal (ULN) for age.
  • 2.Alanine aminotransferase (ALT) >2.5 times the ULN.
  • 3.High risk intermediate-2 or high risk MDS or acute leukemia.

研究者

发起方
ovartis Pharmaceuticals Corporation

相似试验